BerGenBio

Share Issue/Capital Change • Feb 14, 2019

BerGenBio ASA: Exercise of share options and increase of capital

BerGenBio ASA: Exercise of share options and increase of capital

Bergen, Norway, 14 February 2018 - The Board of Directors in BerGenBio ASA (the"Company") (OSE: BGBIO) has, to fulfil the Company's obligations under the option agreements, resolved to increase the Company's share capital by NOK 14,000 by issuance of 140,000 new shares. The new shares are subscribed for by an option owner that wishes and is entitled to exercise options in accordance with the Company's option scheme. The subscription price is in accordance with the prevailing options price pursuant to the Company´s option scheme, NOK 10.62 per share.

The capital increase is expected to be registered within 7 days, and following the issuance of the new shares, the issued share capital of BerGenBio ASA will be NOK 5,485,144.60 consisting of 54,851,446 shares, each with a par value of NOK 0.10.

-End-

Contacts

Richard Godfrey

CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie

CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.